jeudi 15 septembre 2016

Onco Actu du 15 septembre 2016

1. Biologie

Born to be bad? [The evolution and Medicine Review]

3.1 Tabac

FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX® (varenicline) [Pfizer]

FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill [STAT]

FDA panel recommends dropping serious warning on Pfizer's Chantix [Reuters]

3.1.1 Tabac - e-cigs

E-cigarettes 'help thousands successfully quit smoking' [NHS Choices]

4. Dépistage, diagnostic et pronostic

Transport Oncophysics and Pancreatic Cancer [MD Anderson]

Strengthening the foundations for early detection [Cancer Research UK]

4.1 Dép., diag. & prono. - Prostate

Despite thumbs down from professional groups, mass prostate cancer screening events continue, often with misleading promotions [HealthNewsReview]

4.12 Biopsies liquides

Counting cancer cells in blood could be key to telling whether prostate cancer treatment is working [The Institute of Cancer Research]

5. Traitements

High-capacity nanoparticle [MIT News]

BET inhibitor tamps down PD-L1 activity in ovarian cancer cells [FierceBiotech]

Drug that targets stem cells could help treat leukaemia [Cancer Research UK]

5.10 Traitements - Essais

New study compares surgery, radiation, and active surveillance in prostate cancer [ACS]

Men with early prostate cancer can safely opt out of treatment, finds landmark study [STAT]

Prostate Cancer Screening Trial Shows PSA Screening Works! Sort of...... [Forbes]

Monitoring of prostate cancer as effective as treatment in some cases [The Guardian]

Prostate Cancer Study Details Value of Treatments [NY Times]

For prostate cancer, monitoring is an option, but higher metastasis rate is a risk [LA Times]

5.2 Pharma

Richard Gaynor retires from Lilly Oncology; Dana-Farber’s Garraway steps up [FierceBiotech]

Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career [Lilly]

How GlaxoSmithKline Took Its Medicine [Forbes]

5.2.2 Pharma - Fusions & Acquisitions

Takeda sets aside $15B for U.S. buys after topsy-turvy R&D week: FT [FierceBiotech]

5.3 Traitements - FDA, EMA,...

Spectrum bladder cancer drug not effective: U.S. FDA panel [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

EU approval for Eisai kidney cancer treatment [PharmaFile]

European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy [Ipsen]

6. Lutte contre les cancers

The Impact and Future of the Childhood Cancer Survivor Study: An Interview with Greg Armstrong, M.D. [NCI]

6.10 Politiques

UN panel urges wider access to medicines, but pharma slams the report [STAT]

U.N. panel challenges market-based approach to drug R&D [Reuters]

6.9 Controverses

The 7 biggest problems facing science, according to 270 scientists [Vox]